Drug Profile
A 91883A
Latest Information Update: 02 Feb 2001
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antivirals
- Mechanism of Action HIV envelope protein gp120 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 02 Feb 2001 Profile reviewed but no significant changes made
- 13 Jul 1998 No-Development-Reported for HIV infections treatment in USA (Unknown route)
- 24 Aug 1995 New profile